Scott Hansen’s Post

Thyme care : combines 24/7 specialized cancer care navigation services, technology and data insights and oncologist-led therapeutic interventions. Thyme Care developed a tech-enabled care team that integrates with more than 800 oncologists as part of its Thyme Care Oncology Partners for a hybrid collaborative care model, according to the company. The latest capital raise includes $55 million in equity funding backed by existing investors CVS Health Ventures, Town Hall Ventures, a16z Bio + Health, AlleyCorp, Echo Health Ventures, Frist Cressey Ventures and Foresite Capital along with new investor Concord Health Partners. Banc of California will provide an additional $40 million in debt financing Total capital raise so far 178M

The cancer care journey remains a challenging one in today's healthcare system. Navigation, access to timely care, and affordability are just a few of the challenges cancer patients face. We believe Thyme Care’s approach to powering value-based oncology care will dramatically improve the cancer patient, provider, and payor experience by scaling 24/7, technology-enabled virtual navigation, symptom support, palliative care, and more – as well as advanced data insights to improve the cancer care model for everyone. Thyme Care partners with both oncology practices and health plans nationwide, fundamentally aligning incentives across patients, providers, and payors to drive better care quality and outcomes. Congrats to Thyme Care on this most recent $95M Series C fundraise! https://lnkd.in/ger7CNrs None of the above should be taken as investment advice or an advertisement for investment services; please see https://lnkd.in/gjmYWkHi for more information.

🤯 Cancer care costs are SKYROCKETING, placing an unbearable burden on patients, providers, and payers alike. Many attempts have been made to improve the patient experience and reduce cancer care costs. Most have failed. ⁉ Why? ➡ Because patients often encounter fragmented support and coordination gaps between visits, resulting in higher hospitalization rates and increased healthcare expenses. Managing the complexity of cancer diagnosis requires personalized care plans, 24/7 support and navigation, and a combination of clinical and non-clinical care. This is the approach Thyme Care is taking by partnering with oncologists nationwide to deliver comprehensive cancer care support, both in and out of the clinic. 🤝 ❗ Our provider-centric approach is the reason we’ve secured investment from CVS Health Ventures and Echo Health Ventures, the strategic investment platform investing on behalf of multiple Blues health plans. This investment is a milestone moment for Thyme Care, driven by our commitment to working with partners dedicated to rethinking how we deliver and pay for cancer care. Read more here: https://lnkd.in/grHNHTfN

Congratulations to LightOx Ltd for raising £1.5m in investment to support their pioneering work on a groundbreaking treatment for early-stage oral cancer. This funding will help develop LXD191, an oral gel activated by light, targeting a serious pre-cancerous condition called oral epithelial dysplasia (OED). Current treatments are often invasive and painful, affecting 95% of patients and leaving 50% unable to return to work. The investment was made through our North East Innovation Fund, managed by Northstar Ventures UK, along with other investors led by GMC Life Sciences Fund by Praetura and made up of Bruntwood SciTech, Cheshire and Warrington Local Enterprise Partnership and Greater Manchester Combined Authority. Read more here: https://lnkd.in/gD6UmkQh North East Growth Hub The North East Combined Authority Invest South Tyneside South Tyneside Council #Innovation #CancerTreatment #InvestmentSuccess #Biotech #MedicalResearch

We're honored to have been featured in VentureBeat, Fierce Healthcare, Forbes, TechCrunch and many more outlets. The press coverage highlights how we: 🔍 Matched oncology patients and clinical trials with 95% accuracy alongside one of our collaborating cancer centers 🤝 Have onboarded half a dozen early partners, with plans to scale even further these next few months ➡ Help streamline not just patient-trial matching, but also quality reporting, quality improvement initiatives, precharting, clinical pathway workflows and more 👨💻 Raised $15m to continue to raise the bar, including with the latest version of our OncoLLM that outperforms trained experts and GPT-4 alike. 🔗 Article links: https://lnkd.in/gAGR52rs - VentureBeat https://lnkd.in/gBwQ2GSJ - Fierce Healthcare https://lnkd.in/ggnbGHWG - Forbes https://lnkd.in/gjytiJkg - TechCrunch

Exciting Announcement: Free Oncology Provider Dataset Launch on Snowflake Marketplace! Focus: Cancer Diagnostic Services in the U.S. Northeast Payers Covered: UnitedHealthcare, Aetna, Cigna, Elevance We're excited to share our groundbreaking health plan price transparency dataset, specifically tailored for oncology providers. This dataset is a game-changer in understanding and navigating the pricing landscape for cancer diagnostic services in the Northeastern U.S. Why This Matters: Our dataset empowers oncology providers to negotiate higher reimbursement rates using our competitive pricing. Accessible Now: Available for free on the Snowflake Marketplace, this dataset is a testament to our commitment to transparency and innovation in healthcare. Explore and Innovate: Harness this data to enhance your strategic planning and operational efficiency. 👉 Stay Ahead: Follow us for more updates and insights! https://lnkd.in/e6fA6MCP #Oncology #PriceTransparency #SnowflakeMarketplace #DataAnalytics #Snowflake #HealthcareData

#TransformingOncologyCare: Health Catalyst's Strategic Acquisition of Carevive Systems Health Catalyst has acquired Carevīve Systems, enhancing its data and analytics capabilities in cancer treatment. This strategic acquisition promises to revolutionize patient care, clinical research, and operational efficiencies within the oncology sector, setting new benchmarks for data-driven healthcare innovation. Strategic Impact and Market Dynamics: 📈 Synergistic Expansion: By integrating Carevive's oncology-focused platform, Health Catalyst can now offer comprehensive solutions that encompass treatment care planning, clinical trial screening, care coordination, remote patient monitoring, and post-treatment care. 📈 Market Shifts: This acquisition is likely to prompt competitive responses from other healthcare technology providers, potentially leading to a wave of mergers and acquisitions aimed at bolstering oncology capabilities. 📈 Industry Leadership: Health Catalyst's strengthened position in the oncology sector will likely influence market dynamics, positioning the company as a leader in data-driven healthcare solutions. Innovation and Technological Advances: 👩⚕️ Enhanced Data Utilization: The integration of Carevive's platform with Health Catalyst's existing data and analytics technology will provide unprecedented insights into patient-reported outcomes and oncology registry data. 👩⚕️ Patient-Centered Care: Carevive's focus on amplifying the patient's voice in cancer care aligns perfectly with Health Catalyst's mission to leverage data for healthcare improvement. 👩⚕️ Real-World Data Integration: The acquisition will enhance the ability to gather and analyze real-world data, providing researchers with valuable insights that can accelerate the development of new treatments and therapies. Investor Insights and Recommendations: 📈 Investment Opportunities: Investors should consider the potential for growth in companies that are innovating in the oncology sector, particularly those that leverage data and analytics to improve patient care. 📈 Long-Term Value: The focus on patient-centered care and real-world data integration aligns with long-term trends in healthcare. As Health Catalyst and Carevive Systems unite, they are not just enhancing their capabilities; they are pioneering a future where data-driven insights and patient-centered care converge seamlessly. This strategic acquisition marks a pivotal moment in the oncology sector, promising to transform the landscape of cancer care and set new standards for innovation and excellence. Read More: https://lnkd.in/gMjDDgqq #HealthCatalyst #CareviveSystems #OncologyCare #HealthcareInnovation #DataDrivenHealthcare #MarketUnwinded #InvestmentOpportunities #PatientCenteredCare #ClinicalResearch

We are delighted to announce the successful USD $25M first close of our Series B financing, and to welcome our new investor Bristol Myers Squibb as we continue to advance PTT-4256 into the clinic later this year. This Series B financing consists of a new strategic investment from Bristol Myers Squibb (BMS), as well as support from existing investors including Canaan and Brandon Capital. Proceeds from the raise will be used for the continued development of Pathios’ unique approach to cancer immunotherapy focused on the inhibition of GPR65, a novel target that has been genetically associated with a range of immunologically-mediated diseases. This investment comes at an exciting inflection point for Pathios as we progress GPR65 inhibitor PTT-4256 towards our first-in-human clinical trial. We'd like to thank the Pathios team and our collaborators for their incredible work, and our investors who continue to believe in our mission to transform cancer outcomes. To find out more, read the full press release here: https://lnkd.in/dp8XmQwX #fundraising #investment #GPR65 #biotech #clinicaltrials #drugdevelopment #immunotherapy #immunooncology

💪 The power of the CancerX community is truly in action as two of our CancerX members, Cancer Support Community (CSC) and Mika, are joining forces on an exciting and significant effort! 🧠 CSC and Mika Health are working toward distributing an app-based platform aimed at broadening access to mental health services and essential support for individuals undergoing cancer treatments in North America. This initiative marks the introduction of the region's first free AI-enabled evidence-based oncologic digital therapeutic. 🚀 Driven by a passion for innovation and inspired by The White House’s Cancer Moonshot efforts to enhance the patient experience, Sally Werner, CEO of CSC, explains why CSC joined CancerX as a founding member, “CancerX fosters a vibrant ecosystem of collaboration and opportunities between partners that might not otherwise cross paths. In our case, we discovered that our mission priorities aligned strongly with those of Mika Health, a global digital therapeutics developer and one of 16 startup companies selected for CancerX’s Accelerator program’s first cohort.”   🔗 Learn more about the collaboration between CSC and Mika Health: https://lnkd.in/eM75n_VR

Gene&Cell Therapy >> Simone Song's ORI Capital closes $260M second fund after CG Oncology success: Simone Song recalls discussing oncolytic virus therapies with her father and son “under the moonlight, like a family scientific symposium” in Southern California in 2014. After the intergenerational discussion, she posted to WeChat about the subject and, through business connections, was eventually led to Arthur Kuan. Arthur Kuan Song, then a managing director for Greater China healthcare investment banking at Goldman Sachs, would go on to launch her own healthcare VC firm, ORI Capital, a year later. And in 2017, ORI invested in the bladder cancer therapy at CG Oncology, which Kuan stepped into as CEO after previous management ran into troubles with a clinical hold, loss of a CDMO contract and cash reserves that withered to the point of just six weeks of runway, she said. It was one of Song’s best bets as the California biotech sprinted out of the gates last month with a large, upsized IPO that demanded so much interest the stock $CGON popped 95% on its first day of trading. Song looks to replicate the success with the final closing of a second fund, disclosed Thursday morning. At $260 million, ORI Capital plans to invest in more biotechs focused on cancer, metabolic diseases and neurodegenerative disorders, Song said in an interview with Endpoints News. Her parents were basic scientists and drug developers in the first two areas, she said. Across those three areas — buckets that include some of the biggest diseases and leading causes of death in the world — ORI Capital will look at about eight to 10 modalities that it’s steeped in, Song said. That includes cell therapies, RNA therapies, protein degradation and stabilization, among others. It will also invest in diagnostics. Most of the second fund had already been raised, with Song telling financial news service Mergermarket in 2021 that ORI looked to raise a total of $400 million. Last fall, Bloomberg reported the anticipated total would be $300 million. The first fund came in at about $200 million, and it backed companies like CG, TriSalus Life Sciences, Orchard Therapeutics, Kymab and Semma Therapeutics. Many of them have exited already: TriSalus went public via SPAC last August; Orchard went the traditional IPO route but ran into hurdles with its lentiviral gene therapies and eventually sold to Kyowa Kirin last fall; whereas Kymab and Semma sold to Sanofi and Vertex, respectively. ORI has also invested in cell therapy maker AffyImmune, which will begin raising a Series B later this year, Song said. The Hong Kong-based firm is geography-agnostic, Song said, noting she spends about four or five months in the US each year, about two months in Europe and most of the remainder in Asia. Check sizes could be as large as $30 million to $40 million for each portfolio… #lucidquest #genetherapy #celltherapy